Radioactive lipiodol takes aim at inoperable liver tumors
NCT ID NCT05797870
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a targeted radiation therapy called 188Re-SSS lipiodol for people with liver cancer that cannot be surgically removed. The treatment delivers radiation directly to the tumor through the liver's blood vessels. The study aims to see how many patients' tumors shrink within six months. Only 16 participants were planned, but the trial is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
188Re-SSS lipiodol (radioactive substance delivered directly to the liver tumor)
What this could lead to
If it works, this could offer a new treatment option for people with liver cancer that cannot be removed by surgery.
What could go wrong
This is a small, early-phase trial (only 16 people) and is currently suspended. The treatment involves radiation, which can cause side effects like liver damage or fatigue. Success is not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre de Lutte contre le Cancer Eugène Marquis
Rennes, Brittany Region, 35042, France